跳至主要内容
临床试验/NCT01315470
NCT01315470Unknown1 期

Phase 1 Study of the Use of Granulocyte Colony-stimulating Factor for the Treatment of Repeated Implantation Failure in IVF Patients

Hadassah Medical Organization1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2011年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
入组人数
20
试验地点
1
主要终点
pregnancy rate

研究概览

简要总结

The investigators use granulocyte colony-stimulating factor (GCSF) for the treatment of recurrent implantation failure in IVF patient with cause unknown or due to thin endometrium. Several studies showed that GCSF improves embryo development and implantation and increase pregnancy rate.

详细描述

The investigators use granulocyte colony-stimulating factor (GCSF) for the treatment of repeated implantation failure (5 cycles) in IVF patient with cause unknown or due to thin endometrium. we intend to treat with GCSF during the IVF cycle if thin endometrium (<6 mm) is the cause for the treatment failure, and during the implantation window if cause unknown.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • women after 5 failures in IVF cycles with cause unknown.
  • women after 5 failures in IVF due to thin endometrium (<6 mm) and unresponsive to estrogen supplements.

排除标准

  • history of hematology disease
  • allergy to GCSF
  • neutrophilia
  • severe lower back pain
  • liver dysfunction
  • hyperuricemia
  • a recent febrile disease or pneumonia
  • rheumatoid arthritis
  • sickle cell disease-

研究组 & 干预措施

neupogen

Experimental

干预措施: neupogen administration for women with recurrent IVF failure (Drug)

结局指标

主要结局

pregnancy rate

时间窗: 18 months

次要结局

  • endometrial thickness during IVF treatment(18 months)
  • endometrial thickness(18 months)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验